Global Hormone Refractory Breast Cancer Market, By Treatment Modality (Hormone Receptor-Based Therapy, Tumor Markers Therapy, Gene Therapy, Others), Route of Administration (Intravenous, Subcutaneous, Intramuscular, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Hormone Refractory Breast Cancer Market Analysis and Size
The global hormone refractory breast cancer market is expected to witness significant growth during the forecast period. Breast cancer is the second most common cancer in the world and is the most common cancer in women globally. The global hormone refractory breast cancer market is expected to develop at a favourable rate from 2022 to 2029. The number of people with hormone refractory breast cancer is increasing worldwide. The endlessly improving healthcare infrastructure, along with the increase in disposable incomes of people in Asia Pacific region is expected to make the market grow in the forecast period. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global hormone refractory breast cancer market in the forecast period 2022-2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hormone Refractory Breast Cancer Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Modality (Hormone Receptor-Based Therapy, Tumor Markers Therapy, Gene Therapy, Others), Route of Administration (Intravenous, Subcutaneous, Intramuscular, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany)
|
|
Market Opportunities
|
|
Market Definition
Hormone refractory breast cancer, also known as hormone-resistant, is defined as a condition wherein the breast cancer does not respond or remain ineffective with applying hormonal treatment. Most of advanced breast cancer become hormone- refractory at some extent. The rising need for early diagnosis and the increased focus on R&D efforts by major companies is anticipated to expand the global hormone refractory breast cancer market. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Global Hormone Refractory Breast Cancer Market Dynamics
Drivers
- Increase in Breast Cancer
According to the records of World Health Organization, cancer is the most deadly human disease resulting in the deaths of approximately 8.2 million people worldwide in 2012. Among these deaths, breast cancer was found to be most prominent disease among women that killed around 521,000 individuals. According to World Health Organization (WHO), breast cancer was responsible for around 685 000 deaths worldwide in 2020 approximately. This boost the market growth.
- Rising Demand for Hormone Therapy
Hormone therapies are widely used to treat breast cancer, which causes resistance after long-term usage of hormone therapy in the patients. This resistance to the therapy is termed as hormone refractory breast cancer. Consequently, there is a rising demand for effective hormone therapy in the global hormone refractory breast cancer market. Though, there is a rising likelihood that approved medicines will be accessible in the near future. Thus, these therapeutic demands boost the growth of the market.
Opportunities
- Huge Demand for Tumor markers therapy
Tumor markers therapy is a type of hormone-refractory breast cancer treatment that uses tumor markers to locate and treat tumors. Tumor markers are substances that are made by tumors or released into the blood by tumors. They can be found in the blood, urine, or tissue of people with cancer. These markers are used for diagnosis, staging, and monitoring the response to treatment which is called biomarker-based medicine. Biomarkers may also include proteins and genes that are related with tumor growth and spread (metastasis).
- Better Improvement Than Conventional Therapy
Since no conventional therapy is approved for hormone refractory breast cancer, the global hormone refractory breast cancer market has enormous future potential. Although, there is an increasing possibility that approved medicines will be available in the near future, as medications such as everolimus and trastuzumab, either alone or in combination, are being developed for the effective therapy of hormone refractory breast cancers.
- Increased Research and Development
Hormone refractory breast cancer treatment usage in scientific research has been growing due to factors such as increased prevalence rate of this type of disease that can be used for several biological studies such as clinical trials, preclinical drug discovery, technological advancements in terms of better detection methods, improved therapeutic approaches with higher efficacy rates; new drugs entering into a market that are aimed at finding more effective treatments among others. The use of hormone refractory breast cancer in biological science and technology is increasing at a fast pace. It also helps to identify new biomarkers for cancer diagnosis and treatment. Additionally, it is used for drug screening and development. Thus, the application has enormous potential to improve breast cancer research and treatment. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are not aware of the appropriate treatment methods for this disease could restrain the growth of the global hormone refractory breast cancer market over a forecast period.
- High Cost
The huge expenditure of the treatment methods such as tumor marker therapy, gene expression therapy, gene mutation therapy hamper the market growth.
This global hormone refractory breast cancer market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hormone refractory breast cancer market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hormone Refractory Breast Cancer Market Scope
The global hormone refractory breast cancer market is segmented on the basis of treatment modality, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Modality
- Hormone Receptor-Based Therapy
- Tumor Markers Therapy
- Gene Therapy
- Others
Route of Administration
- Intravenous
- Subcutaneous
- Intramuscular
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Hormone Refractory Breast Cancer Market Regional Analysis/Insights
The global hormone refractory breast cancer market is analysed and market size insights and trends are provided by treatment modality, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global hormone refractory breast cancer market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the increased prevalence of breast cancer, high adoption of hormonal therapies and advanced healthcare facilities
Asia-Pacific dominates the market due to the increased awareness about diseases and rapidly disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hormone Refractory Breast Cancer Market Share Analysis
The global hormone refractory breast cancer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hormone refractory breast cancer market.
Key players operating in the global hormone refractory breast cancer market include:
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Merck KGaA (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
SKU-